Your LVEF of 48% Places You at Significant Risk, But Guideline-Directed Therapy Can Substantially Reduce Heart Failure Progression
With an LVEF of 48%, you fall into the heart failure with mildly reduced ejection fraction (HFmrEF) category, and without appropriate treatment, your risk of heart failure progression over 5 years is substantial—but initiating guideline-directed medical therapy (GDMT) now can meaningfully reduce your risk of hospitalization and death.
Understanding Your Risk Profile
Your LVEF of 48% sits at a critical threshold. Research demonstrates that patients across the 41-49% LVEF spectrum face similarly poor outcomes to those with more severely reduced ejection fraction 1. In a large 5-year outcomes study, patients with borderline ejection fraction (41-49%) had a 75.7% mortality rate over 5 years—essentially identical to those with LVEF ≤40% 1. The median survival for heart failure patients across all ejection fraction categories was only 2.1 years 1.
More concerning: your LVEF category is inherently unstable. Studies show that patients with HFmrEF have less than a 25% probability of remaining in the 41-49% range after just one year 2. Among hospitalized patients with HFmrEF who were followed prospectively, 17% transitioned to HFrEF (LVEF <40%) within one year, and those whose ejection fraction worsened had a 7-fold increased risk of death 3.
The Evidence-Based Path Forward
The most recent 2025 Canadian guidelines 4 and 2022 AHA/ACC/HFSA guidelines 5 provide clear direction for patients like you:
First-Line Therapies (Start These Now):
SGLT2 inhibitors (empagliflozin or dapagliflozin): Class 2a recommendation for reducing heart failure hospitalizations and cardiovascular mortality 5, 4. In the EMPEROR-Preserved trial subgroup with LVEF 41-49%, empagliflozin reduced the composite endpoint of cardiovascular death or HF hospitalization by 21%, driven primarily by a 29% reduction in HF hospitalizations 5.
Diuretics as needed for symptom management 5
Additional Therapies to Consider (Class 2b):
Because your LVEF is on the lower end of the HFmrEF spectrum (48% is closer to 40% than 50%), you may benefit from the same medications proven effective in HFrEF 5:
- ACE inhibitors, ARBs, or ARNi (angiotensin receptor-neprilysin inhibitor)
- Mineralocorticoid receptor antagonists (MRAs)
- Evidence-based beta blockers for HFrEF
The 2022 guidelines specifically note that "patients with LVEF on the lower end of this spectrum appear to respond to medical therapies similarly to patients with HFrEF" 5.
Critical Inflection Points
Research analyzing over 33,000 heart failure patients found that LVEF around 40-50% represents a critical inflection point where event rates begin to increase sharply 6. Below LVEF of 50%, the incidence of cardiovascular death, pump failure death, and heart failure hospitalization all rise substantially 6.
Common Pitfalls to Avoid
Don't wait for symptoms to worsen: The trajectory of your LVEF matters more than the absolute value at any single point 7. Early intervention is crucial.
Don't assume stability: Your LVEF will likely change over time, with considerable within-person variability (standard deviation of 7.4%) 2. Serial monitoring is important, but treatment decisions should not be delayed.
Don't focus solely on LVEF: While LVEF guides initial classification, comprehensive assessment including natriuretic peptides, congestion status, and right ventricular function provides better prognostic information 7, 8.
The Bottom Line
Without treatment, your 5-year prognosis is poor—comparable to patients with more severely reduced ejection fraction. However, starting SGLT2 inhibitors immediately, combined with other guideline-directed therapies appropriate for your lower-range HFmrEF, can significantly reduce your risk of heart failure hospitalization and death over the next 5 years 5, 4.
Your baseline LVEF and right ventricular function are independent predictors of whether your ejection fraction will worsen 3, making early aggressive therapy essential to prevent transition to HFrEF and its associated worse outcomes.